Related content

A Phase II Trial of Prolonged Oral Etoposide (VP-16) as Second-Line Therapy for Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

By Rose P.G.   Blessing J.A.   Lewandowski G.S.   Creasman W.T.   Webster K.D.  

Gynecologic Oncology, Vol. 63, Iss. 1, 1996-10 ,pp. : 101-104

Academic Press

Access to resources Recommend Favorite

A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma

By Hongo Atsushi   Kusumoto Tomoyuki   Nakamura Keiichiro   Seki Noriko   Kodama Junichi   Hiramatsu Yuji  

International Journal of Clinical Oncology, Vol. 15, Iss. 5, 2010-10 ,pp. : 476-483

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

By Koizumi Tomonobu   Yoshiike Fumiaki   Inou Hitoshi   Hatayama Orie   Sasabayashi Mari   Tsushima Kenji   Yamamoto Hiroshi   Hayasaka Muneharu   Kubo Keishi  

Medical Oncology, Vol. 21, Iss. 2, 2004-06 ,pp. : 133-138

Humana Press, Inc

Access to resources Recommend Favorite

Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study

By Thigpen J.T.   Blessing J.A.   Olt G.   Lentz S.S.   Bell J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 581-586

Elsevier

Access to resources Recommend Favorite

Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma

By Hartmann M.   Fedders M.   Schneider A.   Kath R.   Camara O.   Oelschläger H.  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 9, 2007-09 ,pp. : 619-625

Springer Publishing Company

Access to resources Recommend Favorite